Oxygen Biotherapeutics Announces Closing of Its Previously Announced Private Placement of Unregistered Convertible Notes and Warrants

Oxygen Biotherapeutics, Inc. OXBT today announced that it closed its previously announced private placement of unregistered convertible notes and unregistered warrants. The final amount of transaction was $4.9 million, an increase from the previously reported $4.6 million, as a result of an additional $0.3 million in Notes and Warrants that were offered and sold to an additional institutional investor. The transaction resulted in gross proceeds of $4.9 million to Oxygen, excluding any proceeds from exercise of the Warrants, and aggregate placement agent fees of approximately $297,000.